leadf
logo-loader
viewErgomed PLC

Ergomed CEO says acquisition strategy should demand higher share price

Dr Miroslav Reljanovic, chief executive of Ergomed (LON:ERGO), says the company believes it can increase its share price further, which he claims is still undervalued even after a 20% rise over the last six months. Reljanovic believes the acquisition strategy, coupled with newsflow over the coming months, should help the stock to continue its journey north. Ergomed’s CEO says it’s hard to pin down the exact size of the potential market but says the market for oncology treatments in general is

“Metal Tiger has made more than five times that of its total investment and still holds a significant, albeit not notifiable, number of shares in New World,” said chief executive Cameron Parry.

Dr Miroslav Reljanovic, chief executive of Ergomed (LON:ERGO), says the company believes it can increase its share price further, which he claims is still undervalued even after a 20% rise over the last six months.

Reljanovic believes the acquisition strategy, coupled with newsflow over the coming months, should help the stock to continue its journey north.

Ergomed’s CEO says it’s hard to pin down the exact size of the potential market but says the market for oncology treatments in general is very large. The company floated on AIM in July last year, raising £11mln to fund its ambitious growth plans.

Quick facts: Ergomed PLC

Price: 805 GBX

AIM:ERGO
Market: AIM
Market Cap: £392.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

2 min read